GROWTH-HORMONE-RELEASING HORMONE ANALOG / METABOLIC RESEARCH
Tesamorelin
A synthetic GHRH analog investigated in endocrine and metabolic research, with controlled human evidence in defined clinical populations.
At a Glance
PRIMARY RESEARCH AREAS
Growth hormone-releasing hormone signaling; GH/IGF-1 axis; visceral adipose tissue; HIV-associated lipodystrophy; hepatic fat; body-composition and metabolic research.
EVIDENCE LEVEL
Controlled human clinical evidence exists, including randomized trials in defined populations. The strongest evidence concerns reduction of excess abdominal visceral fat in adults with HIV-associated lipodystrophy. Evidence from this specific population should not be generalized to routine weight loss, bodybuilding, anti-aging, or other unstudied uses.
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone that stimulates pituitary growth hormone secretion and increases downstream IGF-1 signaling. Unlike many research peptides, tesamorelin has been evaluated in multiple randomized human trials and has a defined FDA-approved indication involving excess abdominal fat in adults with HIV-associated lipodystrophy.
Overview
Tesamorelin is a stabilized synthetic analogue of human growth hormone-releasing hormone. It acts at pituitary GHRH receptors to stimulate endogenous, pulsatile growth hormone secretion rather than functioning as exogenous growth hormone itself. Clinical research has focused particularly on adults with HIV-associated lipodystrophy and excess visceral abdominal adiposity. Studies have examined visceral adipose tissue, body composition, IGF-1, lipid and metabolic variables, liver fat, safety, and durability following discontinuation. Findings involving HIV-associated lipodystrophy should not automatically be extrapolated to general obesity, athletic performance, muscle gain, anti-aging, or other uses.
Research Context
Altered fat distribution and accumulation of visceral adipose tissue have historically been important metabolic complications in some people living with HIV, particularly with older antiretroviral treatment patterns. Because growth hormone secretion can be altered in visceral adiposity, investigators studied whether stimulating endogenous GH secretion through GHRH signaling could modify body composition while preserving physiological regulation of the GH axis. Subsequent research has investigated hepatic fat accumulation and markers associated with nonalcoholic fatty liver disease in people with HIV.
Mechanism / Biological Context
Overlapping research areas provide a rationale for studying the constituents together, but they do not establish additive or synergistic effects.
Published Research
Evidence for GLOW should be read as separate GHK-Cu, BPC-157, and thymosin beta-4 / TB-500 contexts rather than as evidence for a single tested product. The concise evidence matrix below summarizes the cellular, preclinical, and human landscape.
Limitations / What Remains Unknown
Tesamorelin has considerably stronger human evidence than many experimental peptides, but the strongest controlled evidence concerns adults with HIV-associated lipodystrophy or related metabolic abnormalities. Changes in visceral adipose tissue may diminish following discontinuation. Additional research remains relevant to long-term metabolic outcomes, population-specific responses, hepatic outcomes, glucose regulation, uncommon adverse events, and sustained GH/IGF-1-axis exposure.
References
Falutz J, Allas S, Blot K, et al. Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. New England Journal of Medicine. 2007;357:2359–2370. DOI: 10.1056/NEJMoa072375. Falutz J, Allas S, Mamputu JC, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22:1719–1728. Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312:380–389. Stanley TL, Fourman LT, Zheng I, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. The Lancet HIV. 2019;6:e821–e830.
References and claims are limited to evidence that can be verified for the exact compound or formulation.
Evidence Landscape
Evidence involving individual constituents should be interpreted according to the exact compound, formulation, route, population and endpoint studied. Controlled human evidence specifically evaluating the combined 50 mg GHK-Cu / 10 mg BPC-157 / 10 mg TB-500 formulation has not been established.
CELLULAR / IN-VITRO EVIDENCE
Cellular and receptor-level research provides mechanistic context for GHRH-receptor signaling and downstream regulation of the GH/IGF-1 axis. Such evidence does not independently establish clinical changes in body composition, liver fat, or other human outcomes.
ANIMAL / PRECLINICAL EVIDENCE
Preclinical research involving GHRH signaling and the GH/IGF-1 axis contributes to understanding metabolism, adipose tissue, and endocrine physiology. Clinical interpretation should prioritize direct human trial findings.
Human Evidence
Tesamorelin has a meaningful controlled human evidence base. Randomized trials in adults with HIV-associated abdominal fat accumulation demonstrated reductions in visceral adipose tissue and evaluated body composition, IGF-1, lipid variables, glucose-related measures, adverse events, and tolerability. Additional controlled human research has examined hepatic fat and liver-related outcomes in people living with HIV.
Key Findings by Research Area
Visceral adipose tissue: randomized trials demonstrate reductions in visceral abdominal adipose tissue in adults with HIV-associated lipodystrophy or excess abdominal fat. GH/IGF-1 axis: human research demonstrates stimulation of endogenous GH-related signaling and increases in IGF-1. Hepatic fat: controlled research in people living with HIV has reported reductions in hepatic fat. Durability: reductions in visceral adipose tissue may not be fully maintained after treatment withdrawal. Broader body-composition or anti-aging claims are not established by this population-specific evidence.
Safety & Tolerability Evidence
Safety has been evaluated across randomized clinical trials and longer-term studies in defined HIV populations. Studies have monitored IGF-1 concentrations, glucose-related variables, adverse events, and metabolic outcomes. Reported events have included injection-site reactions and other treatment-emergent events. Controlled human safety data do not establish safety for unstudied populations or uses.
Research Gaps & Interpretation
Important research questions include longer-term metabolic and hepatic outcomes, durability following discontinuation, population-specific responses, glucose-related effects, sustained GH/IGF-1-axis exposure, and uncommon adverse events. The largest interpretive limitation is generalizability: evidence involving HIV-associated visceral adiposity should not be presented as evidence for generalized weight loss, bodybuilding, athletic performance, or anti-aging applications.
Editorial Review
EDITORIALLY REVIEWED
LAST REVIEWED
Research profile reviewed for source accuracy, evidence classification, GHRH and GH/IGF-1 physiology, controlled human evidence, population specificity, safety evidence, and distinction between demonstrated clinical outcomes and broader extrapolated claims.